ViQi partnered with PharmaNest to create FibroNest™, the first multi-vendor and fully translational quantitative AI digital pathology image analysis method for phenotypic quantification of fibrosis and its associated features.

Using FibroNest™, PharmaNest customers experience fully automated fibrosis phenotypic quantification services from digital images of stained slides for research and preclinical drug development projects. ViQi’s cloud based platform efficiently processes very large slides, allowing users to effectively experiment and easily blend standard image analysis algorithms with the power of advanced machine learning. 

 
 

The workflow of the FibroNest™ operations run on ViQi’s cloud based platform, which allows for the uploading of digital images (materials) from PharmaNest clients, image analysis using FibroNest™, and client data generation by the PharmaNest team. The digital pathology component of FibroNest™ (branded under ViQi) is offered as a SaaS service to PharmaNest’s clients.

Image 1. Example of single-fiber detection and phenotyping

Image 2: Example of Cell Phenotyping

Image 3: Example of fibrosis and steatosis detection

Image 4: Example of tumor detection

 

FibroNest™ Features

  • Single-fiber analysis for high sensitivity and precision Fibrosis estimation. FibroNest’s continuous score is patented and validated in clinical trials.

  • Single-vacuole analysis for robust Steatosis estimation.

  • Single-cell analysis detects inflammation and other fibrosis-associated phenotypes

  • Tissue analysis for QC, Region of Interest definition and tissue-wide health metrics

  • OncoNest introduces tumor detection and quantification component providing oncology associated scores for Fibrosis

  • Spatial biology component introduces inflammatory regions and foci detection and quantification. 

  • FibroNest™ Predict can rapidly generate a predictive assay of any available clinical variable. 

  • ViQi’s powerful web-based spatial visualization and ML platform aid in exploration and understanding of the factors leading to generated predictions enabling population statistics as well as single-object interrogation.

  • FibroNest™ is multi-vendor, supports various stains and fluorescent multiplexing

  • ViQi’s cloud-based platform and distributed computation enables PharmaNest to process an entire clinical trial worth of data in less than a week!

PharmaNest & ViQi Collaboration

PharmaNest’s use of a state-of-the-art and powerful FibroNest™ Image Analysis Tool, co-developed with ViQi, and their very good understanding of their clients' needs have been instrumental to the company's success.

 

“ViQi has enabled us to become leaders in the development and distribution of new standards for fibrosis quantification.”

— Mathieu M. Petitjean, Ph.D. CEO, PharmaNest

 
 

Select publications

screenshot

Novel Digital Pathology quantitative image analysis and AI method detects the treatment effect of NASH drug candidates with a performance that benchmarks Imaging based measurements. Li Chen (1), Elizabeth Brown (2), Anne Minnich (2), Vipul Baxi (2), Dimple Pandya (2), Edgar D. Charles (2), Zachary Goodman (3),  Shuyan Du (2), Mathieu Petitjean (1), Arun J. Sanyal (4). (1) Pharmanest, Princeton, NJ, USA (2)  Bristol Myers Squibb, Princeton, NJ, USA (3) Inova Health Systems, Falls Church, VA (4) Virginia Commonwealth University, Richmond, VA, USA. 2022.

screenshot

Multimodality assessment of hepatic fibrosis: Ranked paired reading and artificial intelligence identifies fibrosis improvement with Aramchol missed by conventional staging. V. Ratziu1 , Y. Yilmaz 2 , D. Lazas 3 , S.L. Friedman 4 , C. Lackner 5 , C. Behling 6 , OW. Cummings 7 , Li Chen 8 , M. Petitjean 8 , Y. Gilgun-Sherki 9 , S. Kadosh 10 , and A. J. Sanyal 11. (1) Sorbonne Université, Institute for Cardiometabolism and Nutrition (ICAN) and Hôpital Pitié- Salpêtrière, INSERM UMRS 1138 CRC, Paris, France; (2) Liver Research Unit, Institute of Gastroenterology, Marmara University, and Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey; (3) ObjectiveGI, Inc., Nashville, TN, USA; (4) Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; (5) Institute of Pathology, Medical University of Graz, Graz, Austria; (6) Department of Pathology, Sharp Health System, San Diego, CA, USA; (7) Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States; (8) Pharmanest, Inc. Princeton, NJ, USA; (9) Galmed pharmaceuticals Ltd. Tel-Aviv Israel; (10) Statexcellence Ltd. Israel; (11) Department of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA. 2021.

To learn more about FibroNest or how ViQi can help with your digital pathology needs, please contact us.